FDA New Meeting Has A Controversial Subject
(AmericanProsperity.com) – Following the Supreme Court’s decision to overturn the landmark ruling in Roe v. Wade, many states heavily restricted or banned abortion altogether. A pharmaceutical company applied to have its birth control made available over the counter (OTC) not long after the high court’s ruling. The Food and Drug Administration (FDA) has agreed to have a joint meeting to discuss the company’s application.
FDA schedules meeting on OTC birth control pill application https://t.co/wbwEOWY3nG pic.twitter.com/lVd2cETqen
— The Hill (@thehill) September 12, 2022
Perrigo’s HRA Pharma announced the meeting in a press release on September 12, explaining it wishes to switch its Opill® from a prescription medication to one that consumers can access OTC. The meeting is slated for November 18 and will involve the company and both the FDA’s Obstetrics, Reproductive, and Urologic Drugs Advisory Committee and Nonprescription Drugs Advisory Committee.
If the FDA approves the move, the company’s Opill® would be the first daily birth control pill available for women to buy OTC in the US. The change could greatly increase the accessibility of the drug, although a simple approval won’t necessarily guarantee better access. Insurance companies aren’t legally obligated to cover OTC medications.
The news comes not long after the House passed the Right to Contraception Act in July, which will codify access to contraceptives such as birth control, intrauterine devices, and condoms at the federal level. Several countries in Asia, Africa, and Latin America already have birth control medication available without a prescription.
~Here’s to Your Prosperity!
Copyright 2022, AmericanProsperity.com